Key Highlights

• The European Commission granted Marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe), the first global regulatory approval of obicetrapib.

• NewAmsterdam initiated the SPINOZA Phase 2b trial evaluating obicetrapib in preclinical Alzheimer's disease.

• The PREVAIL interim analysis is planned for Q4 2026, with results expected in Q1 2027.

• Cash, cash equivalents, and marketable securities stood at $643.1 million as of September 30, 2026.

NewAmsterdam Pharma Company N.V.(NASDAQ:NAMS), a clinical-stage biopharmaceutical company developing non-statin oral medicines for patients at risk of cardiovascular disease with elevated LDL cholesterol, reported a series of regulatory and clinical milestones in its third-quarter 2026 update. Most notably, the company's lead asset, obicetrapib, received its first regulatory approval anywhere in the world following the European Commission's decision to authorize both the monotherapy and fixed-dose combination formulations.

European Approval Marks a Watershed Moment

In September 2026, the European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg fixed-dose combination) for patients with primary hypercholesterolaemia, including heterozygous familial and non-familial types, as well as mixed dyslipidaemia. The approval followed a positive opinion from the European Medicines Agency's CHMP and was supported by data from the Phase 3 BROADWAY, BROOKLYN, and TANDEM trials, which demonstrated LDL-C reductions of up to 40% with monotherapy and approximately 50% with the combination versus placebo.

Under its licensing agreement, Menarini holds exclusive commercialization rights across Europe and plans to launch in Germany by year-end 2026 and in the United Kingdom in 2027. NewAmsterdam is entitled to tiered double-digit royalties ranging from the low double-digits to mid-twenties on net sales, along with up to €817 million in potential milestone payments.

Clinical Pipeline Continues to Expand

Beyond the European approval, NewAmsterdam initiated the SPINOZA Phase 2b trial evaluating obicetrapib in preclinical Alzheimer's disease, representing an expansion of the drug's potential therapeutic applications. The company presented three analyses at the European Society of Cardiology Congress 2026, including pooled Phase 3 efficacy data that underscored consistent lipid-lowering results across the program.

The PREVAIL cardiovascular outcomes trial, which enrolled more than 9,500 patients, remains a central near-term catalyst. The company expects to reach the predefined event number for an interim analysis during Q4 2026, with results anticipated in Q1 2027. Top-line data from the Phase 3 RUBENS trial are also expected around year-end.

Several additional studies remain underway, including the REMBRANDT trial using coronary computed tomography angiography to evaluate obicetrapib's effect on coronary plaque composition, and the VERMEER trial investigating the obicetrapib-ezetimibe combination in patients with statin-associated muscle symptoms.

Financial Position Supports Extended Runway

NewAmsterdam ended the third quarter with $643.1 million in cash, cash equivalents, and marketable securities. The company's CEO, Michael Davidson, noted that the PREVAIL interim analysis and RUBENS data readout are among the upcoming catalysts expected to further build the evidence base for obicetrapib across cardiovascular disease and emerging areas of unmet need. With European commercialization underway through Menarini and multiple late-stage trials advancing, NewAmsterdam's financial resources appear positioned to support operations through its next phase of development.

What It All Means

NewAmsterdam Pharma has entered a pivotal period as it transitions from a development-stage company toward potential commercial-stage status. The European approval of obicetrapib establishes a regulatory precedent, while the upcoming PREVAIL interim analysis could serve as a defining event for the program's cardiovascular outcomes story. With a cash position exceeding $600 million, multiple ongoing Phase 3 trials, and a commercial partner executing on European launches, the company's near-term calendar is packed with potential inflection points that could shape its trajectory through 2027 and beyond.